Allterum Therapeutics is developing a monoclonal antibody against IL-7Rα for the treatment of pediatric acute lymphoblastic leukemia (ALL). Developing
treatments for ALL.
Allterum Therapeutics, Inc., is a biopharmaceutical company developing a monoclonal antibody therapy for pediatric patients with relapsed acute lymphoblastic leukemia. Allterum was founded in 2018 by Fannin Innovation Studio in Houston, TX.

Why Allterum Therapeutics


Frontline Therapy for ALL

Pediatric cases make up the vast majority of ALL diagnoses. Although current chemotherapy is very effective, lifelong side-effects from chemotherapy can be debilitating. Allterum seeks to expand our therapy into frontline combinations with the goal of improving response rates above 90%, while diminishing the toxic burden of current treatments.


Relapsed/Refractory T-Cell ALL

Allterum is initially focusing on developing therapies for patients with relapsed disease who may not have effective standard options available to them. In particular, patients with relapsed/refractory T-cell ALL, while relatively rare, have a relatively poor prognosis as a result of a lack of effective therapies.


Lymphomas and other T-cell Diseases

Allterum is actively identifying other cancers of T-cell origin where patients may benefit from treatment with our monoclonal antibody.

Our Partnerships & Collaborators


Allterum is a Fannin Innovation Studio company.

Fannin Innovation Studio is Houston's most active early-stage life sciences development group with the primary focus being on development of early stage assets, in partnership with our academic collaborators. The studio’s assests include internally developed assets like Brevitest and in-licensed assets from academic institutions including local Houstonian institutions such as MD Anderson Cancer Center, Baylor College of Medicine, Rice University, Houston Methodist, Texas A&M, Texas Children’s, University of Texas, and University of Houston.


Advancing an innovative solution for a critical and unmet medical need